<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362683">
  <stage>Registered</stage>
  <submitdate>5/07/2012</submitdate>
  <approvaldate>9/07/2012</approvaldate>
  <actrnumber>ACTRN12612000729820</actrnumber>
  <trial_identification>
    <studytitle>The effect of saffron supplementation on vision in patients with early dry age-related macular degeneration</studytitle>
    <scientifictitle>Patients with atrophic age-related macular degeneration and the effect of saffron supplementation compared with placebo in improving visual and electrophysiological outcomes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Age-related macular degeneration</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral Saffron supplementation with 20 mg daily for a 3 month period with possible time period extension based on results.
There is no wash out period.</interventions>
    <comparator>Placebo treatment with a gelatin capsule daily</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Visual Function as assessed by ETDRS visual acuity</outcome>
      <timepoint>visual acuity will be assessed monthly for 6 months using a standardised ETDRS (early treatment of diabetic retinopathy study) visual acuity chart</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Visual Function as assessed by multifocal electroretinogram findings</outcome>
      <timepoint>Multifocal electroretinography will be performed at baseline, 3 and 6 month data points</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Visual Function as assessed by flicker frequency microperimetry</outcome>
      <timepoint>Perimetry performed at baseline, 3 and 6 month data points</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life as assessed by NEI-VFQ 25</outcome>
      <timepoint>NEI-VFQ 25 performed at baseline, 3 and 6 month data points</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Clinical diagnosis of age-related macular degeneration (AMD) as determined by a qualified retinal specialist
Ability to participate in electroretinographic examination</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Significant ocular media opacities
Other retinal disease (i.e. diabetes, glaucoma, retinal vascular disease) 
Neovascular AMD     
Presence of small bowel or liver disease impairing oral tablet absorption</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients with diagnosed atrophic macular degeneration will be invited to participate at the Sydney Retina Clinic &amp; Day Surgery, Australia. All patients will be treated with either saffron (20 mg/day, oral supplementation) or placebo for a period of 3 months, and then crossed over to the alternate treatment arm for a further 3 months. allocation not concealed.</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>14/07/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of Sydney</primarysponsorname>
    <primarysponsoraddress>The University of Sydney
NSW 2006
Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Melbourne Lord Mayors Charitable fund (Pilot study)</fundingname>
      <fundingaddress>Lord Mayor's Office,
5/140 Queen Street
Melbourne, Victoria, 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Save Sight Institute</sponsorname>
      <sponsoraddress>8 Macquaries Street
Sydney NSW 2000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Age-related macular degeneration (AMD) is a common cause of visual loss in older people, and currently treatment options for dry AMD are limited. This study will investigate whether saffron supplements are an effective treatment for dry AMD.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Local Health Network HREC</ethicname>
      <ethicaddress>Research Development Office
Royal Prince Alfred Hospital 
Missendon Road
Camperdown, NSW, 2050</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Peter McCluskey</name>
      <address>Save Sight Institute,
Sydney Hospital,
8 Macquarie Street,
Sydney, NSW, 2000</address>
      <phone>+61 2 9382 7300</phone>
      <fax />
      <email>petermccluskey@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Geoffrey Broadhead</name>
      <address>Sydney Retina Clinic &amp; Day Surgery
Level 13, Park House
187 Macquarie Street
Sydney, NSW, 2000</address>
      <phone>+61 2 9221 3755</phone>
      <fax />
      <email>gbroadhead@sydneyretina.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>